Melanotan II: mechanism of action

Melanotan II (MT-II) is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family [1]. It is a cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and it is described in the literature as a synthetic analogue of melanocyte-stimulating hormone [3]. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for the compound, so none are stated here. The identifiers that the evidence does give are pharmacological and regulatory rather than structural: it is unlicensed, its sale is illegal in the United Kingdom, and it circulates largely through social media promotion rather than through regulated supply [1][3].

The pathway the work centres on is melanocortin receptor signalling, a family of Class A G protein-coupled receptors with five subtypes (MC1R through MC5R) and roles spanning pigmentation, steroidogenesis, and energy homeostasis [6]. Melanotan II acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and producing skin pigmentation independent of sun exposure [1].

Research Studies

Melanotan II and melanocortin 1 receptor activation in melanocytes

The primary mechanism attributed to Melanotan II in the evidence is MC1R agonism on melanocytes, driving eumelanin synthesis and pigmentation that does not require ultraviolet exposure [1]. This is a receptor-level description rather than a clinical outcome, and it is the mechanism that the case literature uses to explain observed pigmentation changes in people who self-administer the compound [1]. The melanocortin receptor family is characterised as centrally and peripherally expressed, with pigmentation among its recognised physiological roles [6].

Melanotan II and oral mucosal pigmentation in a self-administering patient

A case report followed a patient for three months after self-administered Melanotan II injections given over a period of 64 days, with the stated goal of achieving a deeper tanning effect [1]. On initial intraoral examination, brown pigmentation was observed [1]. The report frames the finding against the compound's MC1R-mediated stimulation of eumelanin production, and notes that despite its popularity the compound remains unregulated and is associated with a range of potential adverse effects [1]. This is a single-patient observation, not a controlled comparison.

Melanotan II and repigmentation in stable nonsegmental vitiligo

An interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. The population is adults with stable nonsegmental vitiligo, and the design is randomised and controlled against standard phototherapy as the backbone [2]. The record describes the trial as evaluating the compound in that adjunctive role; it does not report results.

Melanotan II and oral mucosal malignant melanoma: a reported case

A published case reports a 22-year-old female who developed a mass in the anterior maxilla after using a Melanotan II nasal spray for tanning purposes [3]. The spray is described as containing a synthetic analogue of melanocyte-stimulating hormone, and the report situates the case within the broader context of unlicensed and illegally sold tanning products [3]. This is a single case report and does not establish causation.

Melanotan II and HPA-axis-related behaviour in chronically stressed male rats

In male rats exposed to a model of chronic unpredictable stress, the ACTH(4-10) synthetic analogs Semax and Melanotan II were examined for antidepressant-like and antistress effects [4]. The rationale given is that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis are important in the pathogenesis of depression, and that existing antidepressant therapy has substantial limitations [4]. This work is animal-only; the findings are reported in male rats and cannot be extended to humans on the basis of this evidence.

Melanotan II and analytical identification in seized samples

In a laboratory identification exercise, samples including two vials with a pharmaceutical appearance were submitted for analysis, and the powder contained in a vial was characterised using HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS [5]. The work is presented as a description of the analytical characteristics observed during testing of the submitted material [5]. It is an analytical chemistry report, not a pharmacological or clinical study.

Melanotan II and melanocortin receptor tool-compound pharmacology

A review of recommended tool compounds for the melanocortin receptor GPCRs describes the family as five subtypes of Class A GPCRs with physiological roles including pigmentation, steroidogenesis, and energy homeostasis, and notes that some roles remain to be fully characterised [6]. Apart from the melanocortin-2 receptor (MC2R), the evidence block does not detail subtype-by-subtype selectivity data for Melanotan II, so no selectivity profile is asserted here. The review is a pharmacological reference point for how melanocortin compounds are classified and compared.

Melanotan II and the regulatory and supply context of the evidence

Across the sources, a consistent contextual feature is that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3]. The case literature attributes its spread to social media promotion and notes that use is associated with a range of potential adverse effects [1]. The analytical report documents that material presented as a pharmaceutical-style vial can be submitted for identification and characterised by chromatographic and mass spectrometric methods [5]. These are descriptions of the supply and identification landscape, not efficacy findings.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. The evidence summarised here is drawn from case reports, a trial record, an animal study, and analytical work, and it is not a basis for self-administration.

Sources

• [1] Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report — https://europepmc.org/article/PMC/PMC12942211
• [2] Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo — https://clinicaltrials.gov/study/NCT07437560
• [3] Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — https://pubmed.ncbi.nlm.nih.gov/40210573/
• [4] Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress — https://pubmed.ncbi.nlm.nih.gov/39442746/
• [5] Barbie drug identification: Not a child's play — https://pubmed.ncbi.nlm.nih.gov/39302005/
• [6] Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) — https://europepmc.org/article/PMC/PMC11406693